- ISIN
- CA98420Q2071
- CUSIP
- 98420Q207
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 28, 2018
Highlights
- Market Cap
- $3.09M
- Enterprise Value
- $2.87M
- EPS (TTM)
- -$5.51
- Gross Profit (TTM)
- -$84.11K
- EBITDA (TTM)
- -$2.93M
- Year Range
- $1.72 - $7.05
- ROA (TTM)
- -128.11%
- ROE (TTM)
- -214.03%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
XRTX Performance Chart
XORTX Therapeutics Inc. (XRTX) is down 21.0% since the beginning of the year. At $2 per share, XRTX is trading 68.5% below its 52-week high of $7. Investors who bought $1,000 worth of XRTX shares 5 years ago would now be looking at an investment worth $23.
Loading charts...
Returns By Period
XORTX Therapeutics Inc. (XRTX) has returned -21.00% so far this year and -52.44% over the past 12 months.
XORTX Therapeutics Inc.
- 1D
- 0.91%
- 1M
- -25.50%
- YTD
- -21.00%
- 6M
- -29.97%
- 1Y
- -52.44%
- 3Y*
- -58.76%
- 5Y*
- -52.79%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
XRTX Monthly Returns History
Based on dividend-adjusted daily data since Nov 25, 2019, XRTX's average daily return is +0.16%, while the average monthly return is -1.32%.
Historically, 39% of months were positive and 61% were negative. The best month was Aug 2021 with a return of +157.7%, while the worst month was Oct 2023 at -49.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.
On a daily basis, XRTX closed higher 40% of trading days. The best single day was Aug 29, 2024 with a return of +134.8%, while the worst single day was May 19, 2020 at -45.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.12% | -17.92% | -0.24% | 39.85% | -19.58% | -3.48% | -21.00% | ||||||
| 2025 | -15.90% | 3.14% | -2.02% | 6.27% | -7.86% | -3.72% | -20.15% | 11.32% | 0.65% | -25.58% | 7.62% | -13.33% | -50.25% |
| 2024 | 3.03% | 27.73% | 21.71% | -31.08% | 0.98% | -26.21% | -5.55% | 17.02% | -21.90% | -12.81% | -11.18% | -11.06% | -51.10% |
| 2023 | -26.98% | -0.22% | -21.00% | 37.71% | 4.22% | -2.76% | 1.66% | 1.52% | -10.46% | -49.48% | -10.52% | -5.33% | -68.23% |
| 2022 | -24.88% | -8.44% | 38.30% | -33.33% | -1.54% | 10.16% | -3.55% | -0.74% | -10.37% | -30.17% | 2.96% | -7.13% | -60.59% |
| 2021 | 99.57% | -6.35% | -26.15% | -9.68% | 1.52% | -9.40% | 4.06% | 157.73% | 14.26% | -41.07% | -17.38% | -12.02% | 50.53% |
Benchmark Metrics
XORTX Therapeutics Inc. has an annualized alpha of 35.70%, beta of 0.63, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 29, 2019.
- This stock participated in 210.10% of S&P 500 Index downside but only -29.68% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.63 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 35.70%
- Beta
- 0.63
- R²
- 0.01
- Upside Capture
- -29.68%
- Downside Capture
- 210.10%
Return for Risk
Risk / Return Rank
XRTX ranks 18 for risk / return — in the bottom 18% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for XORTX Therapeutics Inc. (XRTX) and compare them to S&P 500 Index.
| XRTX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.52 | 2.24 | -2.76 |
Sortino ratioReturn per unit of downside risk | -0.36 | 3.07 | -3.43 |
Omega ratioGain probability vs. loss probability | 0.96 | 1.41 | -0.45 |
Calmar ratioReturn relative to maximum drawdown | -0.77 | 2.93 | -3.69 |
Martin ratioReturn relative to average drawdown | -1.22 | 13.52 | -14.74 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the XORTX Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the XORTX Therapeutics Inc. was 99.46%, occurring on Mar 26, 2026. The portfolio has not yet recovered.
The current XORTX Therapeutics Inc. drawdown is 99.31%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.46%Mar 2026 | 4y 6mo | — | 4y 9moSep 2021 - now |
2020 bear market2020 | -68.52%Dec 2020 | 6mo 19d | 1mo 16d | 8mo 5dMay 2020 - Jan 2021 |
2021 bear market2021 | -59.76%Jun 2021 | 4mo 27d | 1mo 28d | 6mo 25dJan 2021 - Aug 2021 |
COVID crash2020 | -55.40%Mar 2020 | 3mo 1d | 1mo 29d | 5moDec 2019 - May 2020 |
2021 bear market2021 | -25.65%Aug 2021 | 9d | 5d | 14dAug 2021 - Sep 2021 |
Drawdown Indicators
| XRTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.46% | -56.78% | -42.68% |
Max Drawdown (1Y)Largest decline over 1 year | -68.64% | -9.10% | -59.54% |
Max Drawdown (3Y)Largest decline over 3 years | -95.21% | -18.90% | -76.31% |
Max Drawdown (5Y)Largest decline over 5 years | -99.46% | -25.43% | -74.03% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.31% | -0.74% | -98.57% |
Average DrawdownAverage peak-to-trough decline | -79.67% | -10.72% | -68.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.98% | 1.97% | +41.01% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of XORTX Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how XORTX Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for XRTX in comparison with other companies in the Biotechnology industry. Currently, XRTX has a P/B value of 2.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with XRTX
Add XORTX Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with XRTX